This story was originally posted on July 28.

By Justin Petrone

Affy's 10-percent revenue decline in the second quarter, due to a loss of market share to competitors and rival technologies, has caused its new CEO to "reassess" the company's strategy and focus.

During his first earnings call as CEO, Frank Witney acknowledged the challenges the firm faces and admitted that Affy has been "slow to respond to technology changes" in the market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.